Hif2alpha inhibitor rcc merck
Web12 de mai. de 2024 · It is an oral, first-in-class, first-in-human HIF-2α inhibitor that targets the transcription factor HIF-2α. Clear cell RCC is defined by VHL alterations that lead to … Web28 de nov. de 2016 · A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors: Actual Study Start Date : December 7, 2016: Actual Primary Completion Date : January 12, 2024: Estimated Study Completion Date : April 14, 2025
Hif2alpha inhibitor rcc merck
Did you know?
Web14 de ago. de 2024 · Merck announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) … Web19 de fev. de 2024 · 611 Background: Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in RCC. MK-6482 is a first-in-class small molecule …
Web24 de jan. de 2024 · Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued … WebBackground. Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC). PT2977 is a potent and selective small …
Web20 de jul. de 2024 · The pivotal phase 3 CONTACT-03 trial has been launched with the goal of exploring the combination of the multikinase inhibitor cabozantinib (Cabometyx) with the PD-L1 inhibitor atezolizumab (Tecentriq) in patients with advanced renal cell carcinoma (RCC) and prior exposure to an immune-checkpoint inhibitor. 1 CONTACT-03 is … WebINTRODUCTION. Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all kidney cancers ().Clear cell renal cell carcinoma (ccRCC) is the …
Web25 de mai. de 2024 · MK-6482, a potent, selective, small molecule HIF-2α inhibitor, has shown favorable safety and antitumor activity in a phase 1/2 study. We present initial results of the open-label phase 2 study of MK-6482 for treatment of VHL-associated ccRCC (NCT03401788).
WebNew HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas Endocr Relat Cancer. 2024 Sep;24(9):C9-C19. doi: 10.1530/ERC-16-0479. Epub 2024 Jun 30. Author Rodrigo Almeida Toledo 1 Affiliation 1 Division of Hematology and Medical ... sias registered assessorWeb16 de fev. de 2024 · TPS399. Background: Combination therapy with the PD-1 inhibitor pembrolizumab and the vascular endothelial growth factor (VEGF) inhibitor lenvatinib showed antitumor activity as first-line treatment for advanced clear cell RCC (ccRCC) in the phase 3 KEYNOTE-581/CLEAR study (NCT02811861). Antitumor activity has also been … the people cubeWeb6 de nov. de 2024 · MK-6482, a HIF-2α inhibitor, has moved into a phase 3 trial for further testing of its efficacy and safety among patients with previously treated clear cell renal … siass acatlanWeb2 de mar. de 2024 · HIF-2α can accumulate and be overactivated due to the inactivation of the Von Hippel-Lindau (VHL) tumor suppressor gene, which occurs in most RCC cases. MK-6482 is a potent and selective small molecule inhibitor of HIF-2α that has shown antitumor activity in a phase I/II study in patients with pretreated, advanced ccRCC (NCT02974738). sias researchWeb2 de mar. de 2024 · 273 Background: Clear cell RCC (ccRCC) accounts for ~70% of kidney cancer cases in the US. Several first-line therapies are approved for ccRCC, but few patients respond completely and most progress within 5-11 mo. A key oncogenic driver in RCC is the transcription factor hypoxia-inducible factor 2α (HIF-2α). MK-6482 is a small … the people cultWeb15 de dez. de 2011 · Consequently, VHL-deficient RCC cell lines cannot degrade HIFα subunits in an O 2-dependent manner, and have been used extensively to investigate the roles of HIF1α and HIF2α in tumour growth. sias reverse scoringWeb12 de nov. de 2024 · Has experienced disease progression on or after having received systemic. treatment for locally advanced or metastatic RCC with a PD-(L)1 checkpoint inhibitor (in sequence or in combination with a vascular endothelial growth ... 3475-03B MK-3475-03B ( Other Identifier: Merck ) 2024-003610-13 ( EudraCT Number ) First … the people daily